Canagliflozin disrupts T cell activation

Nat Rev Nephrol. 2023 Aug;19(8):478. doi: 10.1038/s41581-023-00739-4.
No abstract available

Publication types

  • Comment

MeSH terms

  • Canagliflozin* / pharmacology
  • Canagliflozin* / therapeutic use
  • Diabetes Mellitus, Type 2* / drug therapy
  • Humans
  • Hypoglycemic Agents
  • T-Lymphocytes

Substances

  • Canagliflozin
  • Hypoglycemic Agents